Context: First cause of seeking for urologic consultation in the world, chronic prostatitis is a real public health care problem. Objective: Analyze epidemioclinical aspect of chronic prostatitis/chronic pelvic pain syndrome (CP∕CPPS) and proceed in management assessment. Patients and methods: Descriptive Prospective and analytique study about all CP/CPPS admitted in our service from 1st January 2016 to 30 October 2016. Results: Fifty fours (54) patients have been enrolled, accounting for 9.85% of our activities. Mean age: 36.24±13.44. The majorities (87, 50%) of our patients were celibataire or married, but living separated to their wife. They were doing anxiogenic and prolonged sitting activities (Car driver, Seller, Tailor). The most frequent (60%) clinical manifestation was Pelviperineal and/or testicular pain. Complaints were often associated to uretrovesical obstruction and irritation Signs, sexual dysfunction. Digital rectal examination tenderness was the only physical examination founding. We found solely 4 cases of PCB type II with E Coli as germ responsible. PCNB type IIIA was the most prevalent (48%). Systematical antibiotherapy based on quinolone using alone or in combination with azithromycin has been adopted. It’s associated to AINS, alpha blockers and anxiolytis. Therapeutic result has been evaluated during 4-6 months after treatment and was judged satisfactory (NIH-CPSI decrease of 6 points) for 72.50% patients. Conclusion: Multimodal treatment taking account to the main symptom and socioprofessional habits is the only way for good result. It necessary to found new bio markers in the aim to help for diagnostic and treatment result assessment.
| Published in | American Journal of Biomedical and Life Sciences (Volume 10, Issue 1) |
| DOI | 10.11648/j.ajbls.20221001.12 |
| Page(s) | 7-11 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Chronic Prostatitis, Pelviperineal Pain, Expressed Prostatic Secretion, Digital Rectal Xamination
| [1] | Calhoun E, Mc Naughton, Collins M et al. The economic impact of chronic prostatitis. Arch Intern med 2004; 164: 1234-36. |
| [2] | Litwin MS, Mc Naughton, Collins M et al. The national institute of health chronic Prostatitis symptom index development and validation of a new outcome measure. Chronic prostatitis collaborative research Network. J Urol 1999; 162: 369. |
| [3] | Mehik A, Hellstrom P, Sarpola A et al. Fears sexual disturbances and personality features in men with prostatitis: a population based cross sectional study in finland. BJU Int 2001; 88: 35-38. |
| [4] | Shaun Wen H L, Men long L, Kah Hay Y et al. Adverse impact of sexual dysfunction in chronic prostatitis chronic pelvic pain syndrome. Urology 2008; 71: 79-84. |
| [5] | Caldamone AA, Emilson LBU, Al juburi A et al: prostatitis prostatic secretory dysfunction affecting fertility. Fertil Steril 1980; 34: 602. |
| [6] | Li HJ. Outline of the effects of chronic prostatitis on male fertility. Chinese journal of Andrology 2006; 12: 99-103. |
| [7] | Nickel JC, Alexander RB, Schaeffer et al. Chronic prostatitis collaborative research Network study group: leucocytes and bacteria in men with chronic prostatitis chronic pelvic pain syndrome compared to asymptomatic controls. J Urol 2003; 170: 818-27. |
| [8] | Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and Urethritis. Invest Urol 1968; 5: 492-512. |
| [9] | Stamey TA. Urinary infection in men. Pathogenesis and treatment of urinary tract Infection. Baltimore. Williams and Williams co, 1980, 343-429. |
| [10] | Kiyota H, Onoder S, Ohishi Y et al. Questionnaire survey of Japanese urologists concerning the diagnosis and treatment of chronic prostatitis and chronic pelvic pain syndrome. Int J Urol 2003; 10: 636-42. |
| [11] | Poleti F, Medicini MC, Alinovi A et al. Isolation of chlamydiae Trachomatis from the prostatic cells in patients affected by non-acute abacterial prostatitis. J Urol 1985; 124: 651. |
| [12] | Weidner W, Schiefer HG et al. chronic prostatitis: A thorough search for etiologically involved microorganisms in 1461 patients. Infect 1991, 19 suppl 3: 119-125. |
| [13] | Propert KJ, Litwin MS ET al. Responsiveness of the national institut of health. Chronic Prostatitis symptoms index NIH CPSI QOL research 2006; 15: 299-305. |
APA Style
Salifou Issiaka Traore, Ousmane Dembélé, Madou Traore, Soumaila Traore, Aly Boubacar Diallo, et al. (2022). Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. American Journal of Biomedical and Life Sciences, 10(1), 7-11. https://doi.org/10.11648/j.ajbls.20221001.12
ACS Style
Salifou Issiaka Traore; Ousmane Dembélé; Madou Traore; Soumaila Traore; Aly Boubacar Diallo, et al. Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Am. J. Biomed. Life Sci. 2022, 10(1), 7-11. doi: 10.11648/j.ajbls.20221001.12
AMA Style
Salifou Issiaka Traore, Ousmane Dembélé, Madou Traore, Soumaila Traore, Aly Boubacar Diallo, et al. Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Am J Biomed Life Sci. 2022;10(1):7-11. doi: 10.11648/j.ajbls.20221001.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajbls.20221001.12,
author = {Salifou Issiaka Traore and Ousmane Dembélé and Madou Traore and Soumaila Traore and Aly Boubacar Diallo and Layes Toure and Mousssa Diassana and Bathio Traore and Amadou Kassogué and Idrissa Goita and Kateneme Seydou Ouattara},
title = {Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome},
journal = {American Journal of Biomedical and Life Sciences},
volume = {10},
number = {1},
pages = {7-11},
doi = {10.11648/j.ajbls.20221001.12},
url = {https://doi.org/10.11648/j.ajbls.20221001.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20221001.12},
abstract = {Context: First cause of seeking for urologic consultation in the world, chronic prostatitis is a real public health care problem. Objective: Analyze epidemioclinical aspect of chronic prostatitis/chronic pelvic pain syndrome (CP∕CPPS) and proceed in management assessment. Patients and methods: Descriptive Prospective and analytique study about all CP/CPPS admitted in our service from 1st January 2016 to 30 October 2016. Results: Fifty fours (54) patients have been enrolled, accounting for 9.85% of our activities. Mean age: 36.24±13.44. The majorities (87, 50%) of our patients were celibataire or married, but living separated to their wife. They were doing anxiogenic and prolonged sitting activities (Car driver, Seller, Tailor). The most frequent (60%) clinical manifestation was Pelviperineal and/or testicular pain. Complaints were often associated to uretrovesical obstruction and irritation Signs, sexual dysfunction. Digital rectal examination tenderness was the only physical examination founding. We found solely 4 cases of PCB type II with E Coli as germ responsible. PCNB type IIIA was the most prevalent (48%). Systematical antibiotherapy based on quinolone using alone or in combination with azithromycin has been adopted. It’s associated to AINS, alpha blockers and anxiolytis. Therapeutic result has been evaluated during 4-6 months after treatment and was judged satisfactory (NIH-CPSI decrease of 6 points) for 72.50% patients. Conclusion: Multimodal treatment taking account to the main symptom and socioprofessional habits is the only way for good result. It necessary to found new bio markers in the aim to help for diagnostic and treatment result assessment.},
year = {2022}
}
TY - JOUR T1 - Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome AU - Salifou Issiaka Traore AU - Ousmane Dembélé AU - Madou Traore AU - Soumaila Traore AU - Aly Boubacar Diallo AU - Layes Toure AU - Mousssa Diassana AU - Bathio Traore AU - Amadou Kassogué AU - Idrissa Goita AU - Kateneme Seydou Ouattara Y1 - 2022/03/03 PY - 2022 N1 - https://doi.org/10.11648/j.ajbls.20221001.12 DO - 10.11648/j.ajbls.20221001.12 T2 - American Journal of Biomedical and Life Sciences JF - American Journal of Biomedical and Life Sciences JO - American Journal of Biomedical and Life Sciences SP - 7 EP - 11 PB - Science Publishing Group SN - 2330-880X UR - https://doi.org/10.11648/j.ajbls.20221001.12 AB - Context: First cause of seeking for urologic consultation in the world, chronic prostatitis is a real public health care problem. Objective: Analyze epidemioclinical aspect of chronic prostatitis/chronic pelvic pain syndrome (CP∕CPPS) and proceed in management assessment. Patients and methods: Descriptive Prospective and analytique study about all CP/CPPS admitted in our service from 1st January 2016 to 30 October 2016. Results: Fifty fours (54) patients have been enrolled, accounting for 9.85% of our activities. Mean age: 36.24±13.44. The majorities (87, 50%) of our patients were celibataire or married, but living separated to their wife. They were doing anxiogenic and prolonged sitting activities (Car driver, Seller, Tailor). The most frequent (60%) clinical manifestation was Pelviperineal and/or testicular pain. Complaints were often associated to uretrovesical obstruction and irritation Signs, sexual dysfunction. Digital rectal examination tenderness was the only physical examination founding. We found solely 4 cases of PCB type II with E Coli as germ responsible. PCNB type IIIA was the most prevalent (48%). Systematical antibiotherapy based on quinolone using alone or in combination with azithromycin has been adopted. It’s associated to AINS, alpha blockers and anxiolytis. Therapeutic result has been evaluated during 4-6 months after treatment and was judged satisfactory (NIH-CPSI decrease of 6 points) for 72.50% patients. Conclusion: Multimodal treatment taking account to the main symptom and socioprofessional habits is the only way for good result. It necessary to found new bio markers in the aim to help for diagnostic and treatment result assessment. VL - 10 IS - 1 ER -
Email: